Great Lakes Crystal Technologies Quantum Sensors Recognized by Quantum Economic Development Consortium

Report highlights quantum sensors’ role in revolutionizing biomedical technologies

January 29, 2025 — Great Lakes Crystal Technologies (GLCT) was recently recognized in a Quantum Economic Development Consortium (QED-C) report highlighting quantum sensors’ role in revolutionizing biomedical technologies (view article). These sensors promise to enhance diagnostic accuracy, enable less invasive medical procedures, and improve patient outcomes.

GLCT’s core contribution lies in the production of single-crystal diamond substrates – a vital component of quantum sensors. Single-crystal diamon substrates support unparalleled sensitivity, allowing the detection of previously inaccessible biological signals, driving innovation in disease diagnostics, drug development, and medical imaging.

Quantum sensors measure ultra-weak magnetic fields emitted by the human body, enabling non-invasive imaging of the brain, heart, and muscles. This technology offers earlier detection and treatment for conditions like Alzheimer’s, Parkinson’s, and cardiovascular diseases and also supports cellular research in cancer studies and drug metabolism analysis.

“GLCT’s advanced single-crystal, NV-center diamond substrates provide the precision and stability required for these sensitive applications, helping to overcome the key challenge of achieving ultra-high sensitivity in biological environments,” said Dr. Timothy Grotjohn, Co-Founder and CEO of Great Lakes Crystal Technologies, “By partnering with leading research institutions, GLCT aims to unlock new possibilities in subcellular imaging, brain monitoring, and disease detection.”

GLCT is expanding its Michigan-based facilities to meet the growing demand for domestically produced, high-quality, NV-center diamond substrates. 

“Our team’s efforts support the U.S. quantum technology supply chain and strengthen American leadership in the global quantum industry” continued Dr. Timothy Grotjohn.

According to Dr. Timothy Grotjohn, GLCT’s strategic priorities align with the QED-C’s recommendations to foster cross-sector collaboration, increase funding, and support regulatory advancements. These efforts aim to bridge the gap between sensor developers and end-users, enabling faster commercialization and broader adoption of quantum medical technologies. 

“Through partnerships with government, industry, and academia, GLCT is committed to building a future where quantum-enabled healthcare solutions are accessible to all.” 

For more information about Great Lakes Crystal Technologies and its work in advancing quantum sensing, contact quantum@glct.com.